Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;147(1):37-47.
doi: 10.1007/s11060-019-03318-5. Epub 2020 Jan 30.

The role of TP53 gain-of-function mutation in multifocal glioblastoma

Affiliations

The role of TP53 gain-of-function mutation in multifocal glioblastoma

Lauren R Olafson et al. J Neurooncol. 2020 Mar.

Abstract

Purpose: The phenotypic and genotypic landscapes in multifocal glioblastoma (MF GBM) cases can vary greatly among lesions. In a MF GBM patient, the rapid development of a secondary lesion was investigated to determine if a unique genetic signature could account for the apparent increased malignancy of this lesion.

Methods: The primary (G52) and secondary (G53) tumours were resected to develop patient derived models followed by functional assays and multiplatform molecular profiling.

Results: Molecular profiling revealed G52 was wild-type for TP53 while G53 presented with a TP53 missense mutation. Functional studies demonstrated increased proliferation, migration, invasion and colony formation in G53.

Conclusion: This data suggests that the TP53 mutation led to gain-of-function phenotypes and resulted in greater overall oncogenic potential of G53.

Keywords: Gain-of-function; Glioblastoma; Multifocal; TP53.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no conflict of interest.

Figures

Fig. 1
Fig. 1
Pre-operative MRI scans exhibiting two expansive bulky lesions arising in the left thalamus (a and b) and cerebella hemisphere c with an irregular ring contrast enhancement
Fig. 2
Fig. 2
Nucleotide sequence analysis of TP53 exon 8 in G52 and G53 tumour samples. a Wt nucleotide sequence at codon 273. b G52 and G53 tumour nucleotide sequence at codon 273. Dot indicates the position of the C to T nucleotide substitution and c.818G.A (p.R273H) mutation of the TP53 gene in the G53 tumour
Fig. 3
Fig. 3
p53 mutation promotes cell proliferation, migration and invasion in multifocal primary glioblastoma cell lines in vitro. a Real-time xCelligence analysis of proliferation (represented by cell index) of G52 (red) and G53 (black). b 24 h timepoint analysis of proliferation (represented by cell index) levels between G53 and G52. Error bars represent standard deviations. p < 0.1; *p < 0.02. c Real-time xCelligence analysis of migration (represented by cell index) of G53 and G52. d 24 h timepoint analysis of migration (represented by cell index) levels between G53 (left frontal lesion) and G52 (left thalamic lesion). Error bars represent standard deviations. p < 0.1; p < 0.8. e Real-time xCelligence analysis of invasion (represented by cell index) of G53 (black) and G52 (red). f 24 h timepoint analysis of invasion (represented by cell index) levels between G53 (left frontal lesion) and G52 (left thalamic lesion). Error bars represent standard deviations. p < 0.2; p < 0.1
Fig. 4
Fig. 4
Colony formation escalation in a p53 mutant cell line. a G53 colony formation (crystal violet stain) increases across all cell seeding densities (50 to 600 cells) over 14 days compared to G52 (inset magnification × 20). b Colonies were quantified using a stereomicroscope and colony counting pen. G53 colony counts consistently increase over time with increasing cell density, whereas G52 demonstrates no change in formation
Fig. 5
Fig. 5
Higher cell proliferation in p53 mutant. a Labelling index for Ki-67 in G52 and G53 (×40 magnification). b LI was measured as the percentage of positive cells per 1000 cells. *p < 0.05

Similar articles

Cited by

References

    1. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Lasocki A, et al. Multifocal and multicentric glioblastoma: improved characterisation with FLAIR imaging and prognostic implications. J Clin Neurosci. 2016;31:92–98. doi: 10.1016/j.jocn.2016.02.022. - DOI - PubMed
    1. Paulsson AK, et al. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol. 2014;119(2):429–435. doi: 10.1007/s11060-014-1515-1. - DOI - PMC - PubMed
    1. Thomas RP, et al. The incidence and significance of multiple lesions in glioblastoma. J Neurooncol. 2013;112(1):91–97. doi: 10.1007/s11060-012-1030-1. - DOI - PubMed
    1. Hassaneen W, et al. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg. 2011;114(3):576–584. doi: 10.3171/2010.6.JNS091326. - DOI - PubMed